![[SHELL] FDA Approves Deucravacitinib (Sotyktu), First TYK2 Inhibitor for Psoriatic Arthritis](https://cdn.sanity.io/images/0vv8moc6/rheum-microsite/4c18e2ce700234add328b70ae72f3e385c491652-400x400.jpg?w=350&fit=crop&auto=format)
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.
![[SHELL] FDA Approves Deucravacitinib (Sotyktu), First TYK2 Inhibitor for Psoriatic Arthritis](https://cdn.sanity.io/images/0vv8moc6/rheum-microsite/4c18e2ce700234add328b70ae72f3e385c491652-400x400.jpg?w=350&fit=crop&auto=format)
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

The FDA designates litifilimab as a breakthrough therapy for cutaneous lupus erythematosus, highlighting its potential to transform treatment options.